Search

Displaying results 2241 - 2250 of 2674 in total
  1. Drug

    Pizotifen

    go.drugbank.com/drugs/DB06153
    Approved

    Sandomigran is available in a number of countries but is not approved by the FDA nor EMA.

    Categories: Adrenergic alpha-1 Receptor Antagonists, Serotonin Receptor Antagonists
  2. Drug

    Methacholine

    go.drugbank.com/drugs/DB06709
    Approved

    [A229648, L31763] Methacholine was granted FDA approval on October 31, 1986, and is marketed under the trademark PROVOCHOLINE® by Methapharm Inc.[L31763]

    Categories: Cholinergic Receptor Agonist
  3. Drug

    Nifurtimox

    go.drugbank.com/drugs/DB11820
    ApprovedInvestigational

    On August 6 2020, accelerated FDA approval was granted for its use in pediatric patients in response to promising results from phase III clinical trials.

  4. Drug

    Deflazacort

    go.drugbank.com/drugs/DB11921
    Approved

    It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.

    Categories: Corticosteroid Hormone Receptor Agonists
  5. Drug

    Aprocitentan

    go.drugbank.com/drugs/DB15059
    ApprovedInvestigational

    [A263386,L50261] Aprocitentan was approved by the FDA in March 2024 for the treatment of hypertension in patients inadequately controlled with standard therapy. … Endothelin receptor antagonism provides a novel therapeutic pathway for the management of patients with resistant hypertension.

    Categories: Endothelin Receptor Antagonists
  6. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [A274118] Taletrectinib was approved by the US FDA in June 2025 for use in patients with advanced ROS1-positive NSCLC.[L53308,L53523] … It is targeted against ROS1, including resistant mutant forms, and shows some inhibitor activity against tropomyosin receptor kinases (TRKs) TRKA, TRKB, and TRKC.

  7. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808] The FDA approved zidesamtinib on July 22, 2026, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor.

  8. Drug

    NP-6A4

    go.drugbank.com/drugs/DB17599
    Experimental

    NP-6A4 is a peptide designed to specifically bind and activate angiotensin II receptor type 2 (AT2R). It has an Orphan Drug designation from the FDA for pediatric cardiomyopathy.[A258523]

  9. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    Daclatasvir was FDA-approved in July 2015 for use with [DB08934] (Sovaldi) with or without [DB00811] to treat HCV genotype 1 and 3 infections. … The same dosing regimen in treatment-naïve patients with HCV genotype 3 infection with or without cirrhosis achieved SVR12 rates of 71% and 98%, respectively [FDA Label].

  10. Drug

    alpha-Tocopherol acetate

    go.drugbank.com/drugs/DB14003
    Approved

    Alpha-tocopherol is the primary form of vitamin E that is preferentially used by the human body to meet appropriate dietary requirements. In particular, the RRR-alpha-tocopherol (or sometimes called the d-alpha-tocopherol stereoisomer) s...

    Mixtures: O-Cal FA multivitamin